Clinical Implication of UGT1A1 Promoter Polymorphism for Irinotecan Dose Escalation in Metastatic Colorectal Cancer Patients Treated with Bevacizumab Combined with FOLFIRI in the First-line Setting
Lu, Chien-Yu, Huang, Ching-Wen, Wu, I-Chen, Tsai, Hsiang-Lin, Ma, Cheng-Jen, Yeh, Yung-Sung, Chang, Se-Fen, Huang, Meng-Lin, Wang, Jaw-YuanVolume:
8
Language:
english
Journal:
Translational Oncology
DOI:
10.1016/j.tranon.2015.11.002
Date:
December, 2015
File:
PDF, 259 KB
english, 2015